Shares of CSL (ASX:CSL) were flat with a positive bias after it said in a late Tuesday statement that it plans to invest $1.5 billion over the next five years to expand manufacturing of plasma-derived therapies in the US.
The investments are subject to board approval, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments